MedTrace Logo

Study of Parkinson's Early Stage With Deferiprone

NCT02728843 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-04-10

Study results available
· View outcomes & findings →

Summary

The goal of this study is to evaluate the effects of deferiprone, an iron-chelating drug, in patients with Parkinson's disease. Participants will be randomized to receive one of four different dosages of deferiprone or placebo, and will take the assigned study product twice a day for nine months.

Conditions

Interventions

DRUG

Deferiprone

600 mg tablets

DRUG

Placebo

Tablets that match the deferiprone tablets in appearance

Sponsors & Collaborators

  • ApoPharma

    lead INDUSTRY

Principal Investigators

  • David Devos, MD · Hospitalier Régional Universitaire de Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-12
Primary Completion
2019-08-02
Completion
2019-09-04

Countries

  • Canada
  • France
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02728843 on ClinicalTrials.gov